저용량 대 고용량 방사성요오드 치료

키워드

참고문헌 (33)

1. Silberstein EB, "The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0", J Nucl Med, 53(10), pp.1633~1651 (2012)
2. 박정미, "방사성요오드 치료: 경험적 고정용량투여방법에 대한 고찰과 선별적 응용", International Journal of Thyroidology, 6(1), pp.34~42 (2013), 대한갑상선학회
3. Pacini F, "European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium", Eur J Endocrinol, 154(6), pp.787~803 (2006)
4. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules Differentiated Thyroid Cancer, "Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer", Thyroid, 19(11), pp.1167~1214 (2009)
5. Van Nostrand D, "The benefits and risks of I-131 therapy in patients with well-differentiated thyroid cancer", Thyroid, 19(12), pp.1381~1391 (2009)
6. 팽진철, "갑상선암의 방사성요오드 치료에서 선량평가에 기반한 치료용량 결정의 방법과 임상적 유효성", International Journal of Thyroidology, 6(1), pp.43~48 (2013), 대한갑상선학회
7. Arturi F, "Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas", Eur J Endocrinol, 143(5), pp.623~627 (2000)
8. Mazzaferri EL, "Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer", Am J Med, 97(5), pp.418~428 (1994)
9. Sawka AM, "Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer", J Clin Endocrinol Metab, 89(8), pp.3668~3676 (2004)
10. 이가희, "대한갑상선학회 갑상선결절 및 암 진료 권고안 개정안", Endocrinology and Metabolism, 25(4), pp.270~297 (2010), 대한내분비학회
11. Jonklaas J, "Radioiodine therapy in patients with stage I differentiated thyroid cancer", Thyroid, 20(12), pp.1423~1424 (2010)
12. Schvartz C, "Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients", J Clin Endocrinol Metab, 97(5), pp.1526~1535 (2012)
13. Nixon IJ, "The impact of microscopic extrathyroid extension on outcome in patients with clinical T1 and T2 well-differentiated thyroid cancer", Surgery, 150(6), pp.1242~1249 (2011)
14. Nixon IJ, "The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification", Thyroid, 23(6), pp.683~694 (2013)
15. Creach KM, "Radioactive iodine therapy decreases recurrence in thyroid papillary microcarcinoma", ISRN Endocrinol, 2012, pp.816386~ (2012)
16. Mihailovic J, "Influence of initial treatment on the survival and recurrence in patients with differentiated thyroid microcarcinoma", Clin Nucl Med, 38(5), pp.332~338 (2013)
17. Sawka AM, "The impact of thyroid cancer and post-surgical radioactive iodine treatment on the lives of thyroid cancer survivors:a qualitative study", PLoS One, 4(1), pp.e4191~ (2009)
18. Rosario PW, "Salivary and lacrimal gland dysfunction after remnant ablation with radioactive iodine in patients with differentiated thyroid carcinoma prepared with recombinant human thyrotropin", Thyroid, 23(5), pp.617~619 (2013)
19. Brown AP, "The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer", J Clin Endocrinol Metab, 93(2), pp.504~515 (2008)
20. Rubino C, "Second primary malignancies in thyroid cancer patients", Br J Cancer, 89(9), pp.1638~1644 (2003)
21. Sawka AM, "Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis", Thyroid, 19(5), pp.451~457 (2009)
22. Lang BH, "Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy", Surgery, 151(6), pp.844~850 (2012)
23. Rosario PW, "Ultrasonographic differentiation of cervical lymph nodes in patients with papillary thyroid carcinoma after thyroidectomy and radioiodine ablation: a prospective study", Endocr Pract, 20(4), pp.293~298 (2014)
24. Haugen BR, "Radioiodine remnant ablation: current indications and dosing regimens", Endocr Pract, 18(4), pp.604~610 (2012)
25. Bal CS, "Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients", J Clin Endocrinol Metab, 89(4), pp.1666~1673 (2004)
26. Bal C, "A randomized equivalence trial to determine the optimum dose of iodine-131 for remnant ablation in differentiated thyroid cancer", Nucl Med Commun, 33(10), pp.1039~1047 (2012)
27. Mallick U, "Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer", N Engl J Med, 366(18), pp.1674~1685 (2012)
28. Schlumberger M, "Strategies of radioiodine ablation in patients with low-risk thyroid cancer", N Engl J Med, 366(18), pp.1663~1673 (2012)
29. Fallahi B, "Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial", Nucl Med Commun, 33(3), pp.275~282 (2012)
30. Kim EY, "Effects of different doses of radioactive iodine for remnant ablation on successful ablation and on long-term recurrences in patients with differentiated thyroid carcinoma", Nucl Med Commun, 32(10), pp.954~959 (2011)
31. Cheng W, "Lowor high-dose radioiodine remnant ablation for differentiated thyroid carcinoma: a meta-analysis", J Clin Endocrinol Metab, 98(4), pp.1353~1360 (2013)
32. Valachis A, "High versus low radioiodine activity in patients with differentiated thyroid cancer: a meta-analysis", Acta Oncol, 52(6), pp.1055~1061 (2013)
33. Castagna MG, "Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients", Eur J Endocrinol, 169(1), pp.23~29 (2013)

관련 논문AI추천